US Patent 11618787 Methods of treating high risk multiple myeloma
Patent 11618787 was granted and assigned to Janssen Biotech on April, 2023 by the United States Patent and Trademark Office.
All edits
Edits on 18 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 14 Aug, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 14 Aug, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Amy Sasser0
Christopher Chiu0
Jordan Schecter0
Ming Qi0
Tahamtan Ahmadi0
Edits on 2 Aug, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 26 Jul, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 8 Apr, 2023
Golden AI
Edits made to:
Infobox (+23 properties)
Article (+319 characters)
US Patent 11618787 Methods of treating high risk multiple myeloma
Article
Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
116187870
Date of Patent
April 4, 2023
0Patent Application Number
161772390
Date Filed
October 31, 2018
0Patent Citations
Patent Primary Examiner
Find more entities like US Patent 11618787 Methods of treating high risk multiple myeloma
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.